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Abstract
Introduction: People with a1-antitrypsin deficiency are at increased risk for the development of chronic
obstructive pulmonary disease. Previous retrospective epidemiologic studies have found that exposure to
occupational dust among those with a1-antitrypsin deficiency is a risk factor at the group level for poorer lung
function, but on an individual clinical basis, a causal attribution can be difficult to establish.
Case presentation: We describe the case of a 68-year-old Caucasian man with a 25 pack-year smoking history
who presented with new-onset dyspnea on exertion in the setting of workplace dust exposure. During his
evaluation, he was found to have a1-antitrypsin deficiency with evidence of development of pulmonary
emphysema. Workplace spirometric monitoring over 10 years of surveillance for an on-the-job respirator fit
program demonstrated a sharp downward slope in forced expiratory volume in one second, or FEV1, during his
periods of most significant dust exposure, which was attenuated after discontinuation of his workplace exposure.
Conclusion: Patients with a1-antitrypsin disease should be assessed for occupational exposures and closely
monitored for work-accelerated progression of lung function decline. More generally, this case report supports the
biological plausibility of occupationally associated chronic obstructive pulmonary disease, underscoring that work-
associated pulmonary disease can be multi-factorial.
Introduction
On a population level, it is clear that occupational expo-
sure in dusty trades are associated with the development
of chronic obstructive pulmonary disease (COPD) in
healthy individuals without other risk factors [1,2]. On
an individual clinical basis, however, it is difficult to
establish a direct link between a given occupational
exposure and COPD. This even holds true in a1-anti-
trypsin (A1AT) deficiency, a genetic disorder that pre-
disposes individuals to the development of pulmonary
emphysema and supports the biological plausibility of
dust-associated COPD [3-5]. We present a case of
work-related COPD in A1AT deficiency in which attri-
bution was aided by longitudinal lung function data col-
lected prospectively over a protracted period of
occupational exposure as well as through later follow-
up.
Case presentation
A 68-year-old Caucasian man presented with an initial
complaint of dyspnea on exertion that had developed
five years prior and had progressed to shortness of
breath while walking up one flight of stairs. He was a
former cigarette smoker from ages 14 to 30 years, with
am a x i m u mo fo n ea n dah a l fp a c k sp e rd a y( l e s st h a n
25 pack-years total) and no reported respiratory symp-
toms during that period. He experienced significant
inorganic dust exposure while grinding large concrete
aquarium exhibition tanks over a period of 10 years,
ending six years prior to presentation. Less dusty work
exposure continued until his retirement at age 67. He
had no other significant exposure to dusts or fumes.
H i sm e d i c a lh i s t o r yw a sn o t a b l eo n l yf o rap r i o rt r a u -
matic cervical spine injury. His physical examination
revealed pulmonary auscultation that was remarkable
for a prolonged expiratory phase without wheezes or
rhonchi. The remainder of his physical examination was
otherwise unremarkable, except for a left-sided paresis
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his prior spinal injury.
Pulmonary function testing at presentation demon-
strated airflow obstruction: forced expiratory volume in
one second (FEV1) was 2.10 litres (61% of the predicted
value), forced vital capacity (FVC) was 3.60 litres (81%
of the predicted value), the FEV1:FVC ratio was 0.58,
forced expiratory flow over 25% to 75% of the expired
volume (FEF25-75) was 0.85 litres per second (28% of the
predicted value), total lung capacity (TLC) measured by
plethysmography was 6.40 litres (93% of the predicted
value), and residual lung volume (RV) was 2.91 litres
(123% of the predicted value). There was minimal
response to an inhaled bronchodilator. The diffusing
capacity of the lung for carbon monoxide (DLCO)
(hemoglobin-adjusted) was 18.5 ml/min/mmHg (59% of
the predicted value), and the DLCO adjusted for alveolar
volume (VA) was 3.2 (69% of the predicted value). A
computed tomography scan of the chest demonstrated
bilateral lower-lobe-predominant emphysema (Figure 1).
A serum A1AT assay (electrophoresis with agarose
immunofixation) indicated a PiZZ phenotype, with a
quantified value of 24 U (normal ≥ 90 U). Treatment
was initiated with a combination of inhaled fluticasone
and salmeterol twice daily, tiotropium once daily and
albuterol as needed.
Data available from a program of periodic employ-
ment-based spirometric monitoring dating back 16 years
prior to presentation, along with nearly five years of
subsequent follow-up, are shown in Figure 2. Taking
into account 18 serial measurements taken over 241
months, analyzed by least squares regression, the
patient’s FEV1 fell by 77 ml/year, FVC fell by 54 ml/year
and FEF25-75 fell by 110 ml/s/year overall. Using
National Institute for Occupational Safety and Health
(NIOSH) Spirometry Longitudinal Data Analysis (SPIR-
OLA) software for analysis of lung function time trends
[6], the change in FEV1 measured during the period of
employment (-128 ml/year) demonstrated an accelerated
decline relative to the projected normal age-related
decrease of FEV1 (-42 ml/year) [7]. The trajectory of
plotted lung function crosses below the age-based 95th
percentile lower limit of normal (LLN) approximately
midway in this occupational exposure period. After the
patient’s retirement, his FEV1 remained below the LLN,
but the slope of its decline (46 ml/year) shifted closer to
the normal age-related trajectory. The within-person
v a r i a t i o ni nF E V 1 remained within the SPIROLA-based
normal range. The overall slope of the FVC was steeper
than the normal age-predicted decline, but only crossed
the LLN later in follow-up.
To further assess the pattern of change over time, we
remodeled the data in Figure 2 in a “break-point” analy-
sis, jointly estimating linear regression parameter esti-
mates for lung function decline over the periods before
and after the patient’s retirement. For FEV1,t h ep a r a -
meter estimate before retirement was negative (in the
direction of loss) and significant (P < 0.05), but positive,
albeit non-significantly, after his retirement (P =0 . 7 ) .
For FVC, the parameter estimate for the period before
the patient’s retirement was close to zero (P > 0.99), and
post-retirement the parameter estimate deflected nega-
tively (P < 0.05). For FEF25-75, the pre-retirement para-
meter estimate was significantly negative and then
positive after the breakpoint (P < 0.01 for each).
A repeat CT scan of the chest after almost five years
of follow-up showed progression of panlobular severe
emphysema and areas of scarring in the bilateral bases
(not shown). Repeat pulmonary function testing demon-
strated a TLC volume by plethysmography of 6.37 litres
(94% of the predicted value), RV of 3.10 litres (126% of
the predicted value), a RV:TLC ratio of 49%, and DLCO
adjusted for alveolar volume of 2.8 (63% of the predicted
value). To date, the patient has not wished to initiate
A1AT replacement therapy. The patient was recognized
by his employer’sw o r k e r s ’ compensation carrier as hav-
ing COPD attributable in part to his occupational expo-
sure, along with co-attribution to non-work-related
factors (A1AT deficiency and cigarette smoking).
Conclusion
This patient presented with symptomatic airflow
obstruction and emphysema in the context of underly-
ing A1AT deficiency. Importantly, the patient mani-
fested accelerated lung function decline during the
period of highest occupational concrete dust exposure
and attenuated decline once such exposure ceased.
Using a NIOSH-recommended analytic approach, the
decline in FEV1 values from workplace surveillance
Figure 1 Single computed tomography image of the patient’s
chest. Bilateral lower-lobe emphysema with bullae is present,
consistent with panlobular emphysema.
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age-associated slope, but attenuated after occupational
exposure discontinued. This divergence in trajectory is
also consistent with the separate break-point statistical
analysis we performed. Moreover, the patient’sp o s t -
exposure decline in FEV1 (-46 ml/year) is slightly less
than the annual decline that has been reported in
untreated A1AT patients (-60 ± 7 ml/year) [8]. Of note,
we do not have systematic data on symptoms over time
to correlate with the lung function data; for example,
repeated measures using the Borg Dyspnea scale or the
Medical Research Council assessment for shortness of
breath.
Although cigarette smoking is a well-established co-
factor in airflow obstruction and emphysema among
people with A1AT deficiency, occupation has also been
implicated as a risk factor for worse disease status in
several epidemiological studies of A1AT-deficient people
with or without work-related exposures. The largest
study of this question found a lower FEV1 value in
adults ages 50 years and above with PiZZ phenotype
A1AT who self-reported occupational exposures to gas,
fumes or dust for at least three months [3]. Other cross-
sectional observational studies support this association
[4,5]. A recent study also reported accelerated decline in
lung function among 11 rescue workers with mild to
moderate A1AT deficiency (no PiZZ phenotypes)
exposed to dust after the World Trade Center collapse
[9].
Studies of uncontrolled dry concrete grinding opera-
tions have documented very high levels of both respir-
able suspended particulates and silica dust [10]. In non-
A1AT-deficient populations, construction work invol-
ving inorganic dust exposures (which subsumes concrete
finishing) is associated with increased COPD mortality
risk [11], and occupational silica exposure (as noted, an
i m p o r t a n tc o n s t i t u e n to fc o n c r e t ed u s t )i sl i n k e dt o
chronic airflow obstruction [12]. The specific pattern of
exposure and response in our patient, together with the
broader epidemiological evidence [1,2,11,12], is consis-
tent with a relationship between the patient’s dust expo-
sure and his COPD, with the acknowledgment that
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Figure 2 Changes in forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and forced expiratory flow over 25%
to 75% of the expired volume (FEF25-75) over time during periods of heavy workplace dust exposure and light dust exposure as well
as following work discontinuation. Solid line, FVC; dotted line, FEV1; dashed line, FEF25-75.
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our report is unique in describing longitudinal exposure
history coupled with measured lung function data sup-
porting this potential effect-moderating relationship.
People with PiZZ phenotype A1AT disease should be
assessed for occupational exposures and closely moni-
tored for work-accelerated progression of lung function
decline over and above the decline associated with this
disease absent such exposure. More generally, this case
not only points to the biological plausibility of occupa-
tionally associated COPD but also underscores that
work-associated pulmonary disease can be multi-
factorial.
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